Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 1/20 | 0.34 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15930117 | 0.74 | ALDH1A1 (0.38) | ALDH1A1SMN1; SMN2POLBTSHRHSD17B10 | |
| SCHEMBL24759410 | 0.74 | IDH1 (0.40) | IDH1PLA2G7ALDH1A1MAPTHTT | |
| SCHEMBL21267673 | 0.71 | — | — | |
| SCHEMBL17083422 | 0.71 | ALDH1A1 (0.42) | PLA2G7ALDH1A1MAPTHTTSMN1; SMN2 | |
| SCHEMBL18945315 | 0.69 | CHRNB2 (0.34) | ALDH1A1MAPTHTTSMN1; SMN2HSD17B10 | |
| SCHEMBL23171626 | 0.66 | HTR7 (0.35) | ALDH1A1HTTPOLB | |
| SCHEMBL338867 | 0.65 | GABRA1 (0.46) | ALDH1A1MAPTHTTSMN1; SMN2 | |
| SCHEMBL7085860 | 0.65 | GABRA1 (0.42) | ALDH1A1MAPTPOLBTSHRHSD17B10 | |
| SCHEMBL25696492 | 0.63 | NQO2 (0.36) | PLA2G7ALDH1A1SMN1; SMN2HSD17B10 | |
| SCHEMBL25696559 | 0.63 | NOX4 (0.34) | PLA2G7ALDH1A1SMN1; SMN2TSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10208068-B2 | Macrocycles as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180148461-A1 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-05-31 | — | — | US | disclosed |
| US-9611274-B2 | Macrocycles as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148461-A1 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F12 | IDH1 4238/4885PLA2G7 227/4885ALDH1A1 4457/4885 |
| US-10208068-B2 | Macrocycles as factor XIa inhibitors | TFPI, TFPI2, F12 | IDH1 4032/4885PLA2G7 230/4885ALDH1A1 4479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.